Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Registration Number
- NCT00092716
- Lead Sponsor
- Organon and Co
- Brief Summary
The purpose of this study is to determine whether an investigational medication will be more effective than an approved medication in reducing cholesterol levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 655
Inclusion Criteria
- Elevated cholesterol levels
Exclusion Criteria
- Liver disease
- Unstable medical conditions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To evaluate the effect on the reduction in low density lipoprotein cholesterol (LDL-C) after the initial 6-week treatment period.
- Secondary Outcome Measures
Name Time Method Assess safety/tolerability and evaluate effect on HDL-C & on reduction of LDL-C Evaluate % of pts who attain their NCEP-ATP III goal for LDL-C @ each dose level